QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

ANAB

QT62AnaptysBio, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
57.51
+0.74+1.30%
OverviewShort InterestFilings
ANABQT62AnaptysBio, Inc.·NASDAQ
OverviewShort InterestFilings
57.51+1.30%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-1.08
Insider Own-
Shs Outstand29.10M
Perf Week6.03%
Market Cap2.45BForward P/E29.42EPS next Y1.96Insider Trans0.87%Shs Float-Perf Month-3.78%
Enterprise Value2.48BPEG0.17EPS next Q-0.13Inst Own-Short Float-Perf Quarter33.28%
Income-40148146.00P/S10.53EPS this Y-40.74%Inst Trans-Short Ratio-Perf Half Y91.57%
Sales232.39MP/B127.78EPS next Y228.62%ROA-8.13%Short Interest-Perf YTD77.94%
Book/sh0.45P/C363.73EPS next 5Y-ROE442.91%52W High72.36 -20.52%Perf Year262.15%
Cash/sh9.83P/FCF555.24EPS past 3/5Y-ROIC14.06%52W Low11.41 404.03%Perf 3Y-
Dividend Est.-EV/EBITDA42.35Sales past 3/5Y186.43% 25.66%Gross Margin116.42%Volatility3.64% 3.41%Perf 5Y-
Dividend TTM-EV/Sales10.66EPS Y/Y TTM78.91%Oper. Margin17.56%ATR (14)3.21Perf 10Y-
Dividend Ex-Date-Quick Ratio7.58Sales Y/Y TTM154.95%Profit Margin-11.53%RSI (14)53.82Recom2.00
Dividend Gr. 3/5Y-Current Ratio7.58EPS Q/Q-43.75%SMA204.30%Beta1.03Target Price73.67
Payout0.00%Debt/Eq21.76Sales Q/Q-7.14%SMA500.56%Rel Volume1.24Prev Close56.77
Employees136LT Debt/Eq0.32EarningsAug 05SMA20059.53%Avg Volume665.63KPrice57.51
IPO DateJan 26, 2017Option/ShortYes / YesEPS/Sales Surpr.-475.00% 36.84%Net Debt/EBITDA0.49Volume827,833Change1.30%
Analyst Ratings
DateActionAnalystRatingTarget
May-15-26ReiteratedLeerink PartnersOutperform$85 → $90
May-13-26ReiteratedBarclaysOverweight$55 → $75
May-13-26ReiteratedUBSBuy$60 → $76
Apr-28-26ReiteratedLeerink PartnersOutperform$45 → $85
Apr-21-26ReiteratedUBSBuy$70 → $60
Mar-06-26ReiteratedTruist Financial$36 → $50
Mar-05-26ReiteratedStifel NicolausBuy$56 → $85
Mar-04-26ReiteratedH.C. WainwrightBuy$59 → $66
Jan-07-26ReiteratedUBSNeutral$70
Dec-18-25ReiteratedGuggenheimBuy$100 → $140
Latest News
Jun-10-26
Jun-10-2606:20AM
HC Wainwright & Co. Assumes AnaptysBio at Buy, Announces Price Target of $95Benzinga
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue23223591
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A-382164
Gross Profit270232-73
Selling, General and Administrative Excl. Other635142
Research and Development129136164
Other Operating Expense38-3-164
Operating Income4148-115
Interest Expense848050
Unusual Expense
———
Non-Operating Income (Expense)-16-19-20
Net Income Before Taxes-27-13-145
Income Taxes
000
Consolidated Net Income-27-13-145
Net Income From Continuing Operations-27-13-145
Net Income-27-13-145
EPS (Recurring)-0.85-0.46-5.12
EPS (Basic, Before Extraordinaries)-0.85-0.46-5.12
EPS (Diluted)-1.08-0.46-5.12
EBITDA5969-93
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio7.193.85—
Gross Margin116.3898.72-80.22
Operating Margin17.6720.43-126.37
Net Margin-11.64-5.53-159.34
Shares Outstanding292828
Market Capitalization1,668905—
Operating Lease Expense
———
Insider Trading Volume
$59.88$54.74$49.61$44.47$39.33● Close Price0.00M0.93M1.85M2.78M3.70MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Schmid John P.DirectorJun 15 '26Option Exercise0.0012,060037,652Jun 17 12:00 AM
Orwin John ADirectorJun 15 '26Option Exercise0.0012,060016,695Jun 17 12:00 AM
RENTON HOLLINGSDirectorJun 15 '26Option Exercise0.0012,060010,995Jun 17 12:00 AM
Schmid John P.DirectorMar 30 '26Sale56.1120,6451,158,45131,622Apr 01 12:00 AM
Faga DanielPresident, CEOMar 27 '26Sale61.6117,6791,089,199495,965Mar 27 12:00 AM
LOUMEAU ERIC JCHIEF LEGAL OFFICERFeb 11 '26Option Exercise29.7020,000594,00035,000Feb 13 12:00 AM
LOUMEAU ERIC JCHIEF LEGAL OFFICERFeb 11 '26Sale54.0010,000540,00012,835Feb 13 12:00 AM
Marquet MagdaDirectorJan 15 '26Option Exercise26.1122,000574,42020,930Jan 16 12:00 AM
Marquet MagdaDirectorJan 15 '26Sale48.2311,000530,5319,930Jan 16 12:00 AM
LOUMEAU ERIC JCHIEF LEGAL OFFICERJan 08 '26Sale44.712,21098,80912,835Jan 09 12:00 AM
MULROY DENNISCHIEF FINANCIAL OFFICERJan 08 '26Sale44.712,515112,44621,852Jan 09 12:00 AM
Faga DanielPresident, CEOJan 08 '26Sale44.7114,281638,504479,344Jan 09 12:00 AM
Lizzul Paul F.Chief Medical OfficerJan 08 '26Sale44.713,650163,19242,088Jan 09 12:00 AM
LOUMEAU ERIC JCHIEF LEGAL OFFICERJan 07 '26Option Exercise0.0011,776017,662Jan 09 12:00 AM
Faga DanielPresident, CEOJan 07 '26Option Exercise0.0053,6760493,625Jan 09 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR